Sign in Subscribe

retrospective

A collection of 92 issues

HER2 amplification studied in resectable CRC

Skip to content The CRC Digest HER2 amplification studied in resectable CRC A study of 3,607 patients with resectable colorectal cancer investigated the prognostic impact of WES-defined ERBB2 amplification and its association with adjuvant chemotherapy efficacy and circulating tumor DNA. (Int J Clin Oncol) This content is informational only

Study identifies risk factors for irinotecan liver toxicity

Skip to content The CRC Digest ♥ LIVING WITH CRC Study identifies risk factors for irinotecan liver toxicity A retrospective study of 229 cancer patients receiving irinotecan chemotherapy identified key risk factors for hepatotoxicity, which could help clinicians monitor and manage this side effect more effectively. (Frontiers in Oncology) This content

MLH1-Deficient Lynch Syndrome Case Highlights Management Dilemma

Skip to content The CRC Digest MLH1-Deficient Lynch Syndrome Case Highlights Management Dilemma The co-occurrence of a germline MLH1 pathogenic variant and a GALT/dome carcinoma raises questions about optimal management in the absence of high-risk histologic features. (ACG Case Rep J) This content is informational only and does not

Rare GALT/Dome Carcinoma Found in Woman With Lynch Syndrome

Skip to content The CRC Digest Rare GALT/Dome Carcinoma Found in Woman With Lynch Syndrome A woman in her early 40s with MLH1-deficient Lynch syndrome was incidentally found to have a cecal GALT/dome carcinoma during routine surveillance, raising management questions about prophylactic colectomy versus endoscopic surveillance. (ACG Case

Trifluridine/tipiracil outcomes examined in patients 75 and older

Skip to content The CRC Digest ▸ TREATMENT Trifluridine/tipiracil outcomes examined in patients 75 and older A single-center retrospective study compared relative dose intensity, toxicity, and survival between trifluridine/tipiracil (FTD/TPI) monotherapy and FTD/TPI plus bevacizumab in older patients with metastatic colorectal cancer, examining the relationship between dose

Rare DPYD Variant Linked to Severe Fluoropyrimidine Toxicity

Skip to content The CRC Digest ▸ TREATMENT Rare DPYD Variant Linked to Severe Fluoropyrimidine Toxicity A 50-year-old colorectal cancer patient developed life-threatening grade 3-4 toxicities after adjuvant XELOX; sequencing identified a rare intronic DPYD variant (c.2766+3A>T) that causes exon 21 skipping and profound DPD deficiency, which

Anorectal Visits Offer Missed Screening Opportunity for Adults Under 50

Skip to content The CRC Digest ▪ SCREENING Anorectal Visits Offer Missed Screening Opportunity for Adults Under 50 Among 776 patients seen for benign anorectal conditions, only 60.5% of adults aged 45-49 had undergone colonoscopy in the prior 10 years, highlighting a missed opportunity to promote screening during routine visits.

Serbian cohort reveals MLH1 as predominant Lynch syndrome variant

Skip to content The CRC Digest Serbian cohort reveals MLH1 as predominant Lynch syndrome variant Germline testing of 176 high-risk individuals in Serbia identified pathogenic variants predominantly in MLH1, highlighting the need for population-specific genetic testing strategies in hereditary colorectal cancer screening. (Int J Mol Sci) This content is informational

Co-mutations in CREBBP/EP300 and POLE/POLD1 identify high tumor mutational burden in MSS colorectal cancer

Skip to content The CRC Digest Co-mutations in CREBBP/EP300 and POLE/POLD1 identify high tumor mutational burden in MSS colorectal cancer Analysis of over 30,000 tumors found that co-mutation of CREBBP/EP300 and POLE/POLD1 strongly predicted elevated tumor mutational burden in microsatellite-stable disease (median 155.9 vs.

Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer

Skip to content The CRC Digest ▸ TREATMENT Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer A patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer responded to re-challenge with encorafenib and cetuximab combined with nivolumab after prior progression, suggesting this combination may offer renewed